After strong performance over the last two months and a 28% year-to-date share price increase, a valuation check suggests Regeneron’s (NASDAQ:REGN) risk/reward proposition is much less compelling than it was a few months ago.
Thus, in this article, I will focus on a quantitative valuation of the company using a DCF method to demonstrate why I believe it’s time to take profits in Regeneron.
Base Case
DCF analysis, with inputs slightly above analyst estimates, shows that Regeneron's valuation doesn't look attractive.
